DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: :
“Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
Wednesday, May 14, 2014
Targeted failure of the week. Post No 149. Darapladib
GlaxoSmithKline said its drug darapladib had not reduced heart attacks or other major events in patients with acute coronary syndrome, marking another disappointment for the innovative heart medicine.
Darapladib had already failed in a late-stage trial for patients with well-treated heart disease.
No comments:
Post a Comment